202 related articles for article (PubMed ID: 9407964)
1. Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors.
Mortarini R; Anichini A; Di Nicola M; Siena S; Bregni M; Belli F; Molla A; Gianni AM; Parmiani G
Cancer Res; 1997 Dec; 57(24):5534-41. PubMed ID: 9407964
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cells generated either from CD34+ progenitor cells or from monocytes differ in their ability to activate antigen-specific CD8+ T cells.
Ferlazzo G; Wesa A; Wei WZ; Galy A
J Immunol; 1999 Oct; 163(7):3597-604. PubMed ID: 10490952
[TBL] [Abstract][Full Text] [Related]
3. Dendritic type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine-immune cellular network.
Bodey B; Bodey B; Kaiser HE
In Vivo; 1997; 11(4):351-70. PubMed ID: 9292303
[TBL] [Abstract][Full Text] [Related]
4. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro.
Bakker AB; Marland G; de Boer AJ; Huijbens RJ; Danen EH; Adema GJ; Figdor CG
Cancer Res; 1995 Nov; 55(22):5330-4. PubMed ID: 7585596
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis.
Jenne L; Arrighi JF; Jonuleit H; Saurat JH; Hauser C
Cancer Res; 2000 Aug; 60(16):4446-52. PubMed ID: 10969791
[TBL] [Abstract][Full Text] [Related]
6. Induction of cytolytic T lymphocytes against pediatric solid tumors in vitro using autologous dendritic cells pulsed with necrotic primary tumor.
Shilyansky J; Jacobs P; Doffek K; Sugg SL
J Pediatr Surg; 2007 Jan; 42(1):54-61; discussion 61. PubMed ID: 17208541
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
8. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12.
Mortarini R; Borri A; Tragni G; Bersani I; Vegetti C; Bajetta E; Pilotti S; Cerundolo V; Anichini A
Cancer Res; 2000 Jul; 60(13):3559-68. PubMed ID: 10910069
[TBL] [Abstract][Full Text] [Related]
9. Regulation of melanoma epitope-specific cytolytic T lymphocyte response by immature and activated dendritic cells, in vitro.
Mehrotra S; Stevens R; Zengou R; Chakraborty NG; Butterfield LH; Economou JS; Dorsky DI; Mukherji B
Cancer Res; 2003 Sep; 63(17):5607-14. PubMed ID: 14500402
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell subsets generated from CD34+ hematopoietic progenitors can be transfected with mRNA and induce antigen-specific cytotoxic T cell responses.
Ueno H; Tcherepanova I; Reygrobellet O; Laughner E; Ventura C; Palucka AK; Banchereau J
J Immunol Methods; 2004 Feb; 285(2):171-80. PubMed ID: 14980432
[TBL] [Abstract][Full Text] [Related]
11. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene.
Reeves ME; Royal RE; Lam JS; Rosenberg SA; Hwu P
Cancer Res; 1996 Dec; 56(24):5672-7. PubMed ID: 8971174
[TBL] [Abstract][Full Text] [Related]
12. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
[TBL] [Abstract][Full Text] [Related]
13. Generation of CD8+ and CD4+ T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene.
Pérez-Díez A; Butterfield LH; Li L; Chakraborty NG; Economou JS; Mukherji B
Cancer Res; 1998 Dec; 58(23):5305-9. PubMed ID: 9850054
[TBL] [Abstract][Full Text] [Related]
14. Efficient induction of specific cytotoxic T lymphocytes to tumor rejection peptide using functional matured 2 day-cultured dendritic cells derived from human monocytes.
Tanaka F; Yamaguchi H; Haraguchi N; Mashino K; Ohta M; Inoue H; Mori M
Int J Oncol; 2006 Nov; 29(5):1263-8. PubMed ID: 17016660
[TBL] [Abstract][Full Text] [Related]
15. FastDC derived from human monocytes within 48 h effectively prime tumor antigen-specific cytotoxic T cells.
Dauer M; Schad K; Herten J; Junkmann J; Bauer C; Kiefl R; Endres S; Eigler A
J Immunol Methods; 2005 Jul; 302(1-2):145-55. PubMed ID: 15992809
[TBL] [Abstract][Full Text] [Related]
16. Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy.
Oelke M; Moehrle U; Chen JL; Behringer D; Cerundolo V; Lindemann A; Mackensen A
Clin Cancer Res; 2000 May; 6(5):1997-2005. PubMed ID: 10815925
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cell-based vaccines in the setting of peripheral blood stem cell transplantation: CD34+ cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells.
Choi D; Perrin M; Hoffmann S; Chang AE; Ratanatharathorn V; Uberti J; McDonagh KT; Mulé JJ
Clin Cancer Res; 1998 Nov; 4(11):2709-16. PubMed ID: 9829733
[TBL] [Abstract][Full Text] [Related]
18. Generation of dendritic cells from fresh and frozen cord blood CD34+ cells.
Sato K; Nagayama H; Takahashi TA
Cryobiology; 1998 Dec; 37(4):362-71. PubMed ID: 9917353
[TBL] [Abstract][Full Text] [Related]
19. [Killing activity of cytotoxic T lymphocytes stimulated by dendritic cell vaccine loaded with autologous cervical cancer antigen].
Zhou CJ; Ma W; Zhou JD; Zhao YX; Xie HQ
Ai Zheng; 2006 Feb; 25(2):143-7. PubMed ID: 16480575
[TBL] [Abstract][Full Text] [Related]
20. The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells.
Tsang KY; Zhu M; Even J; Gulley J; Arlen P; Schlom J
Cancer Res; 2001 Oct; 61(20):7568-76. PubMed ID: 11606396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
